HC Wainwright Reaffirms 'Sell' Rating for Sarepta Therapeutics

Investment firm maintains bearish outlook on biotech company's stock

Apr. 16, 2026 at 5:23pm

Got story updates? Submit your updates here. ›

A highly detailed, black-and-white close-up image of the intricate gears, wires, and components of a medical device, conveying the technical complexity and financial challenges facing the rare disease drug industry.An extreme close-up of the inner workings of a specialized biotech device highlights the technical complexity and financial challenges facing rare disease drug developers.Cambridge Today

HC Wainwright, an investment research firm, has reaffirmed its 'sell' rating on shares of Sarepta Therapeutics (NASDAQ:SRPT), a biotechnology company focused on developing precision genetic medicines for rare neuromuscular diseases. The firm also maintained its $5.00 target price on the stock, which suggests a potential downside of 76.30% from the company's previous closing price.

Why it matters

Sarepta Therapeutics is a closely watched biotech company in the rare disease space, and the firm's rating and price target could influence investor sentiment and the stock's performance. The 'sell' rating indicates that HC Wainwright believes the company's shares are overvalued and may face significant downside risk.

The details

In its research note, HC Wainwright cited ongoing challenges and uncertainties surrounding Sarepta's pipeline and commercial products. The firm's analysts believe the company's current valuation does not adequately reflect these risks. Other research firms have also issued mixed ratings and price targets for Sarepta, reflecting the complex and competitive nature of the rare disease drug market.

  • The research note was released on Thursday, April 16, 2026.

The players

HC Wainwright

An investment research firm that covers Sarepta Therapeutics and has reaffirmed its 'sell' rating on the company's stock.

Sarepta Therapeutics

A biotechnology company focused on developing precision genetic medicines for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD).

Got photos? Submit your photos here. ›

What’s next

Investors will be closely monitoring Sarepta Therapeutics' future financial and operational performance, as well as any updates on its pipeline and regulatory approvals, to assess the validity of HC Wainwright's bearish stance.

The takeaway

The continued mixed views on Sarepta Therapeutics' prospects highlight the challenges and uncertainties facing the company as it navigates the rare disease drug market. Investors will need to carefully evaluate the company's fundamentals and long-term growth potential to determine the appropriate valuation for the stock.